Literature DB >> 6335402

Inhibition of prothrombinase complex by plasma proteinase inhibitors.

V Ellis, M F Scully, V V Kakkar.   

Abstract

The rate of inactivation of human coagulation factor Xa by the plasma proteinase inhibitors antithrombin III and alpha 1-antitrypsin has been studied in the presence of the accessory components which constitute the prothrombinase complex. The rate of inactivation of factor Xa by antithrombin III was found to be decreased in the presence of phospholipid vesicles with high affinity for factor Xa. The second-order rate constant for the reaction fell from 6.21 X 10(4) to 3.40 X 10(4) M-1 min-1 in the presence of 20 microM phospholipid. Purified factor Va had no effect on the rate of inactivation of factor Xa in the absence of phospholipid. In the presence of phospholipid, factor Va increased the protective effect displayed by phospholipid, further reducing the rate constant to 2.20 X 10(4) M-1 min-1. The rate of inactivation of factor Xa by alpha 1-antitrypsin was unaffected under these conditions. Platelet-bound prothrombinase complex was formed by incubation of factor Xa with washed human platelets activated by a mixture of collagen and thrombin. The prothrombinase activity was inhibited by antithrombin III was a second-order rate constant of 0.85 X 10(4) M-1 min-1. This rate was obtained in both the presence and absence of exogenous factor Va. Platelet factor 3 vesicles, isolated from platelet aggregation supernatants, also formed prothrombinase complex in the presence of factor Va, and this was inhibited by antithrombin III at the same rate as the platelet-bound complex. There was no protection of the platelet-bound prothrombinase complex from inhibition by alpha 1-antitrypsin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6335402     DOI: 10.1021/bi00319a030

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro.

Authors:  Matthew W Bunce; Raffaella Toso; Rodney M Camire
Journal:  Blood       Date:  2010-09-23       Impact factor: 22.113

Review 2.  Novel inhibitors of factor X for use in cardiovascular diseases.

Authors:  F A Spencer; R C Becker
Journal:  Curr Cardiol Rep       Date:  2000-09       Impact factor: 2.931

3.  Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.

Authors:  F A Spencer; S P Ball; Q Zhang; L Liu; S Benoit; R C Becker
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

4.  Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants.

Authors:  Hsiu-Hui Chen; Cristina P Vicente; Li He; Douglas M Tollefsen; Tze-Chein Wun
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

5.  Increased expression of procoagulant activity on the surface of human platelets exposed to heavy-metal compounds.

Authors:  C A Goodwin; C P Wheeler-Jones; S Namiranian; S Bokkala; V V Kakkar; K S Authi; M F Scully
Journal:  Biochem J       Date:  1995-05-15       Impact factor: 3.857

6.  Thrombin activity propagates in space during blood coagulation as an excitation wave.

Authors:  N M Dashkevich; M V Ovanesov; A N Balandina; S S Karamzin; P I Shestakov; N P Soshitova; A A Tokarev; M A Panteleev; F I Ataullakhanov
Journal:  Biophys J       Date:  2012-11-20       Impact factor: 4.033

7.  The effect of Ca2+, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affinity oligosaccharides.

Authors:  T W Barrowcliffe; S J Havercroft; G Kemball-Cook; U Lindahl
Journal:  Biochem J       Date:  1987-04-01       Impact factor: 3.857

8.  The acceleration of the inhibition of platelet prothrombinase complex by heparin.

Authors:  V Ellis; M F Scully; V V Kakkar
Journal:  Biochem J       Date:  1986-01-01       Impact factor: 3.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.